Main cause of death and the costliest complications in diabetic patients are highly associated with cardiovascular disease. Specifically, type 2 diabetes mellitus (T2DM) is a risk factor for developing heart failure (HF).
and β-hydroxybutyrate (βOHB) are alternative energy substrate in ischemic myocardium. Intriguingly, βOHB upregulates oxidative stress resistance factors, including forkhead box O3a (FOXO3a). In a pressure-overloaded HF mouse model, βOHB was elevated in response to oxidative stress in cardiomyocytes. Furthermore, βOHB upregulated superoxide dismutase 2 (SOD2) and catalase, both of which are targets of FOXO3a, and could contribute to cardioprotective effects. 9) In this issue of the Korean Circulation Journal, Oh et al. 10) observed the cardioprotective effect of empagliflozin in both acute and chronic doxorubicin-induced HF models. More importantly, βOHB, increased in the blood by empagliflozin treatment, was identified as a critical mediator to reduce cardiomyocyte apoptosis, suppress the generation of intracellular reactive oxygen species, and improve mitochondrial function. 10) A recent study demonstrated the modulation of circulating ketone levels may represent a novel therapeutic for treatment of HF. In HF patients, application of βOHB exerted beneficial cardiac effects in a dosedependent manner without safety issues. 11) The understanding of how SGLT2 inhibitor might work is critical for future acceptance by clinicians to consider patients with high risk of developing HF. Overall, this novel avenue of research may set a new direction to SGLT2 inhibitor for promoting reverse remodeling in the failing heart.
